MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss

MetaVia Inc.

Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.
Cash and cash equivalents $10.3M at Dec 31, 2025; with Jan 2026 $9.3M offering, funds operations into Q4 2026.
DA-1726 48 mg Phase 1 data: 9.1% weight loss, reduced waist circumference, improved glucose and liver stiffness.
Phase 1 Part 3 titration study (48 mg and 64 mg) IRB approved; dosing starts April 2026, data expected Q4 2026.
Vanoglipel Phase 2a MASH data presented at AASLD; end-of-Phase 2 FDA meeting being scheduled.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MetaVia Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-034907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.